Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

AcuCort

0.59 SEK

-1.01 %

Less than 1K followers

ACUC

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-1.01 %
+1.90 %
-0.84 %
-35.20 %
-7.80 %
+0.41 %
-54.54 %
-83.34 %
-76.85 %

AcuCort is a pharmaceutical company. The company develops and commercializes pharmaceuticals based on well-established substances with a focus on user-friendliness and ease of administration. The company's leading product is an oral film for the acute treatment of allergic reactions and other conditions with high medical demand. Products are aimed at patients and caregivers globally. AcuCort was founded in 2006 and is headquartered in Lund, Sweden.

Read more
Market cap
138.56M SEK
Turnover
47.05K SEK
Revenue
680K
EBIT %
-2,557.35 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20.2
2026

Annual report '25

All
Press releases
ShowingAll content types
Regulatory press release11/28/2025, 9:00 AM

AcuCort AB: AcuCort appoints nomination committee

AcuCort
Regulatory press release10/14/2025, 11:00 AM

AcuCort AB: AcuCort strengthens its management team with the appointment of Anna Chérouvrier Hansson as Business Development Director

AcuCort
Regulatory press release9/25/2025, 7:28 AM

AcuCort AB: AcuCort granted extended SME status by the European Medicines Agency (EMA)

AcuCort

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release9/18/2025, 6:30 AM

AcuCort AB: AcuCort's CEO to present at Life Science Conference in Copenhagen

AcuCort
Regulatory press release8/12/2025, 11:54 AM

AcuCort AB: Sales of Zeqmelit® commenced in Denmark

AcuCort
Regulatory press release6/18/2025, 4:43 PM

AcuCort AB: LSIF invests SEK 1 million in AcuCort through exercise of warrants - strong support ahead of final day for exercising TO 2

AcuCort
Regulatory press release6/17/2025, 11:27 AM

AcuCort AB: AcuCort signs Letter of Intent (LOI) with Glenmark Pharmaceuticals for Germany and five additional European countries

AcuCort
Regulatory press release6/10/2025, 6:30 AM

AcuCort AB: AcuCort signs Letter of Intent (LOI) with Lunatus for the Middle East and Gulf States

AcuCort
Regulatory press release5/26/2025, 11:00 AM

AcuCort AB: AcuCort's drug Zeqmelit® registered as a trademark in Canada

AcuCort
Regulatory press release5/12/2025, 6:00 AM

AcuCort AB: AcuCort receives new order for Zeqmelit® - strong development in the Nordic market

AcuCort
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.